Colistin efficacy in the treatment of multidrug-resistant and extremely drug-resistant gram-negative bacterial infections

Simple item page
dc.contributor.authorÇetin Ç.B.
dc.contributor.authorÖzer Türk D.
dc.contributor.authorŞenol Ş.
dc.contributor.authorDinç Horasan G.
dc.contributor.authorTünger Ö.
dc.date.accessioned2024-07-22T08:12:27Z
dc.date.available2024-07-22T08:12:27Z
dc.date.issued2016
dc.description.abstractBackground/aim: Colistin is used as a salvage therapy for multidrug-resistant and extremely drug-resistant gram-negative bacterial infections. Our aim was to evaluate colistin efficiency and toxicity in the treatment of these resistant gram-negative bacterial infections. Materials and methods: This is a retrospective study carried out in a tertiary care hospital during 2011–2013. Study data were collected from the medical records and consultations of the infectious diseases clinic. Results: The study group included 158 patients with nosocomial infections and 136 (86.1%) of them were hospitalized in the ICU. Respiratory tract infections were the most commonly observed ones (n = 103, 65.2%). The most frequently isolated microorganism was Acinetobacter baumannii (72.2%). A total of 98 (62.0%) patients had clinical cure. There was no statistically significant difference between monotherapy (n = 3/6, 50.0%) and combination therapies (n = 95/152, 62.5%) according to clinical response. Underlying ultimately fatal disease, previous renal disease, and total parenteral nutrition were independent risk factors for poor clinical response. Nephrotoxicity developed in 80 (50.6%) patients and clinical cure was statistically unrelated with nephrotoxicity. Conclusion: Colistin may be used as an effective agent for multidrug-resistant and extremely drug-resistant gram-negative bacterial infections with close monitoring of renal functions, especially for older and critically ill patients. © TÜBİTAK.
dc.identifier.DOI-ID10.3906/sag-1506-125
dc.identifier.issn13000144
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/16068
dc.language.isoEnglish
dc.publisherTurkiye Klinikleri Journal of Medical Sciences
dc.rightsAll Open Access; Hybrid Gold Open Access
dc.subjectAcinetobacter baumannii
dc.subjectAnti-Bacterial Agents
dc.subjectColistin
dc.subjectDrug Resistance, Multiple, Bacterial
dc.subjectGram-Negative Bacterial Infections
dc.subjectHumans
dc.subjectRetrospective Studies
dc.subjectTreatment Outcome
dc.subjectcolistin
dc.subjectantiinfective agent
dc.subjectcolistin
dc.subjectAcinetobacter baumannii
dc.subjectadult
dc.subjectaged
dc.subjectArticle
dc.subjectartificial ventilation
dc.subjectchronic kidney disease
dc.subjectdrug dose reduction
dc.subjectdrug efficacy
dc.subjectdrug withdrawal
dc.subjectEscherichia coli
dc.subjectfemale
dc.subjectGram negative infection
dc.subjecthuman
dc.subjectKlebsiella pneumoniae
dc.subjectmajor clinical study
dc.subjectmale
dc.subjectmonotherapy
dc.subjectmultidrug resistance
dc.subjectnephrotoxicity
dc.subjectparenteral nutrition
dc.subjectPseudomonas aeruginosa
dc.subjectrespiratory tract infection
dc.subjectretrospective study
dc.subjectrisk factor
dc.subjecttreatment outcome
dc.subjectGram negative infection
dc.titleColistin efficacy in the treatment of multidrug-resistant and extremely drug-resistant gram-negative bacterial infections
dc.typeArticle

Files

Collections

Scopus Koleksiyonu